Monday 28 March 2011
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
U.S. regulatory update
Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines is pleased to announce that it met with the U.S. Food and Drug Administration (FDA) for a productive discussion. The FDA has informed the Company of its intention to lift the clinical hold in order to allow the development of MATA-MPL© products to move forward. The Company expects to receive the formal communication from the FDA in the coming weeks.
Manuel Llobet, Chief Executive of Allergy Therapeutics, said:
"We are very pleased to have received positive feedback from the FDA and look forward to providing more information when the formal communication is received."
-Ends-
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Manuel Llobet, Chief Executive Officer |
|
|
Ian Postlethwaite, Finance Director |
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson/ Clare Terlouw |
|
|
Financial Dynamics |
+44 (0) 207 831 3113 |
|
Ben Brewerton/ Susan Quigley |
About Pollinex® Quattro
Pollinex® Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. It is currently available in Europe on a named patient basis.
This information is provided by RNS